Ibrahim Ali1,2, Rajkumar Chinnadurai3, Sara T Ibrahim4, Philip A Kalra3,5. 1. Department of Renal Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK. ibrahim.ali@srft.nhs.uk. 2. Division of Cardiovascular Sciences, University of Manchester, Manchester, M13 9PL, UK. ibrahim.ali@srft.nhs.uk. 3. Department of Renal Medicine, Salford Royal NHS Foundation Trust, Stott Lane, Salford, M6 8HD, UK. 4. Department of Internal Medicine and Nephrology, Faculty of Medicine, Alexandria University, Alexandria, Egypt. 5. Division of Cardiovascular Sciences, University of Manchester, Manchester, M13 9PL, UK.
Abstract
BACKGROUND: Patients with rapidly declining renal function face the dual threat of end-stage renal disease (ESRD) and mortality prior to ESRD. What is less well characterised is whether the pattern of the renal trajectory, linear or non-linear, unmasks subgroups of rapidly progressing patients that face adverse outcomes in a differential manner. METHODS: An individual eGFR slope was applied to all outpatient estimated glomerular filtration rate (eGFR) values for each patient in the Salford Kidney Study from 2002 to 2018 who had at least 2 years follow-up, ≥4 eGFR values and baseline eGFR 15 to < 60 ml/min/1.73m2. Rapid progression was defined as an annual eGFR slope of ≤ - 3 ml/min/1.73m2/yr and patients were categorised as linear or non-linear progressors based on the nature of their eGFR-time graphs. A Fine-Gray competing risk hazard model was used to determine factors associated with progression to ESRD and with mortality prior to ESRD. Cumulative incidence function curves highlighted differences in outcomes between linear and non-linear patients. RESULTS: There were 211 rapidly deteriorating patients with linear eGFR trajectories and 61 rapid non-linear patients in the study cohort. Factors associated with ESRD included younger age, male gender, lower baseline eGFR and higher serum phosphate, whilst older age, history of myocardial infarction and anaemia predicted mortality prior to ESRD. Over a median follow-up of 3.7 years, linear progressors reached ESRD sooner whilst those with non-linear progression faced significantly higher rates of mortality prior to ESRD. CONCLUSIONS: Patients with rapid eGFR decline have high rates of adverse outcomes that are differentially expressed in those progressing linearly and non-linearly as a result of differing phenotypic profiles. Consequently, addressing individual risk factor profiles is important to deliver optimal personalised patient care.
BACKGROUND: Patients with rapidly declining renal function face the dual threat of end-stage renal disease (ESRD) and mortality prior to ESRD. What is less well characterised is whether the pattern of the renal trajectory, linear or non-linear, unmasks subgroups of rapidly progressing patients that face adverse outcomes in a differential manner. METHODS: An individual eGFR slope was applied to all outpatient estimated glomerular filtration rate (eGFR) values for each patient in the Salford Kidney Study from 2002 to 2018 who had at least 2 years follow-up, ≥4 eGFR values and baseline eGFR 15 to < 60 ml/min/1.73m2. Rapid progression was defined as an annual eGFR slope of ≤ - 3 ml/min/1.73m2/yr and patients were categorised as linear or non-linear progressors based on the nature of their eGFR-time graphs. A Fine-Gray competing risk hazard model was used to determine factors associated with progression to ESRD and with mortality prior to ESRD. Cumulative incidence function curves highlighted differences in outcomes between linear and non-linear patients. RESULTS: There were 211 rapidly deteriorating patients with linear eGFR trajectories and 61 rapid non-linear patients in the study cohort. Factors associated with ESRD included younger age, male gender, lower baseline eGFR and higher serum phosphate, whilst older age, history of myocardial infarction and anaemia predicted mortality prior to ESRD. Over a median follow-up of 3.7 years, linear progressors reached ESRD sooner whilst those with non-linear progression faced significantly higher rates of mortality prior to ESRD. CONCLUSIONS: Patients with rapid eGFR decline have high rates of adverse outcomes that are differentially expressed in those progressing linearly and non-linearly as a result of differing phenotypic profiles. Consequently, addressing individual risk factor profiles is important to deliver optimal personalised patient care.
Authors: Navdeep Tangri; Morgan E Grams; Andrew S Levey; Josef Coresh; Lawrence J Appel; Brad C Astor; Gabriel Chodick; Allan J Collins; Ognjenka Djurdjev; C Raina Elley; Marie Evans; Amit X Garg; Stein I Hallan; Lesley A Inker; Sadayoshi Ito; Sun Ha Jee; Csaba P Kovesdy; Florian Kronenberg; Hiddo J Lambers Heerspink; Angharad Marks; Girish N Nadkarni; Sankar D Navaneethan; Robert G Nelson; Stephanie Titze; Mark J Sarnak; Benedicte Stengel; Mark Woodward; Kunitoshi Iseki Journal: JAMA Date: 2016-01-12 Impact factor: 56.272
Authors: Andrew S Levey; Paul E de Jong; Josef Coresh; Meguid El Nahas; Brad C Astor; Kunihiro Matsushita; Ron T Gansevoort; Bertram L Kasiske; Kai-Uwe Eckardt Journal: Kidney Int Date: 2010-12-08 Impact factor: 10.612
Authors: Casey M Rebholz; Josef Coresh; Shoshana H Ballew; Blaithin McMahon; Seamus P Whelton; Elizabeth Selvin; Morgan E Grams Journal: Am J Kidney Dis Date: 2015-03-12 Impact factor: 8.860
Authors: Misghina Weldegiorgis; Dick de Zeeuw; Liang Li; Hans-Henrik Parving; Fan Fan Hou; Giuseppe Remuzzi; Tom Greene; Hiddo J L Heerspink Journal: Am J Kidney Dis Date: 2017-11-16 Impact factor: 8.860
Authors: Gunnar Toft; Uffe Heide-Jørgensen; Heleen van Haalen; Glen James; Katarina Hedman; Henrik Birn; Christian F Christiansen; Reimar W Thomsen Journal: J Nephrol Date: 2019-10-05 Impact factor: 3.902